Warning and Advisories for Healthcare Providers > Letters to Healthcare Providers

Letters to Healthcare Providers   Brukinsa (zanubrutinib), Calquence (acalabrutinib) and Imbruvica (ibrutinib) - Bruton’s Tyrosine Kinase (BTK) Inhibitors: Assessing the potential risk of serious hepatotoxicity (Letter to Healthcare Professionals)       Attachment: Brukinsa   Related Information: Canada: Summary Safety Review: Brukinsa (zanubrutinib), Calquence (acalabrutinib... Posted 2025-12-19 Singapore: New identified risk of hepatotoxicity (including hepatic failure) in ... Posted 2024-10-02